Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study.

Özgüroğlu M., Ahn M., Dong X., Yang J. C., Oizumi S., Goto K., ...Daha Fazla

Clinical cancer research : an official journal of the American Association for Cancer Research, 2026 (SCI-Expanded, Scopus)